Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop...
Stock is near all time lows and probably will make new lows soon. Small chance it tries to test the upper trendline first, in which case I would stop out of the trade above 7.75.
Like CLSD, I would not short this outright, but buy the Jan19 12.5 puts.
MCRB broken out of a falling wedge formation & now breaking out of its resistance zone. We think it will continue upward from here.
* Trade Criteria *
Date First Found- June 20, 2017
Pattern/Why- Falling wedge breakout continuation Long
Entry Target Criteria- Break of $10.87
Exit Target Criteria- $12.77
Stop Loss Criteria- $9.87
Please check back for...